A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine

Menstrually associated migraine (MAM) is often prolonged and difficult to manage with conventional therapies. Frovatriptan is a new selective 5HT(1B/1D) receptor agonist indicated for short-term management of migraine. It has a long half-life and good tolerability. These characteristics suggest that...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2004-07, Vol.63 (2), p.261-269
Hauptverfasser:	SILBERSTEIN, Stephen D, ELKIND, Arthur H, SCHREIBER, Curtis, KEYWOOD, Charlotte
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Biological and medical sciences Carbazoles - administration & dosage Carbazoles - therapeutic use Contraceptives, Oral, Combined - pharmacology Contraceptives, Oral, Hormonal - pharmacology Cross-Over Studies Double-Blind Method Drug Administration Schedule Estrogens - physiology Female Humans Hyperacusis - etiology Hyperacusis - prevention & control Incidence Medical sciences Menstrual Cycle - physiology Migraine Disorders - drug therapy Migraine Disorders - epidemiology Migraine Disorders - etiology Migraine Disorders - physiopathology Migraine Disorders - prevention & control Nausea - etiology Nausea - prevention & control Neurology Patient Compliance Photophobia - etiology Photophobia - prevention & control Serotonin Receptor Agonists - administration & dosage Serotonin Receptor Agonists - therapeutic use Treatment Outcome Tryptamines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!